The Hardest to Treat Hepatitis C Patients Benefit from TMC435
Share
Follow Us
Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients
HUDDINGE, Sweden, May 20, 2011 /PRNewswire/ —
– All TMC435 Patient Subgroups Achieved Substantially Higher SVR4 Rates (Undetectable Virus 4 Weeks After End of Treatment) Compared to pegylated-interferon and ribavirin Alone
– TMC435 was Safe and Well Tolerated at All Doses and Treatment Durations
Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.
Bertil Samuelsson, CSO of Medivir, commented, “We are delighted with the encouraging efficacy and safety results shown by TMC435-based triple therapy over pegylated-interferon and ribavirin, in this 48-Week interim analysis of the ASPIRE study in treatment experienced genotype-1 hepatitis C patients. This patient group is known to be the most difficult one to treat, where in particular prior null and partial responder groups respond very poorly upon retreatment with PegIFN/RBV alone. With several global phase 3 clinical trials ongoing in hepatitis C patients we are expecting the momentum to continue with regards to the development of TMC435.”
Continue reading this entire article:
http://www.prnewswire.com/news-releases/medivir-announces-positive-48-week-interim-data-from-tmc435-hepatitis-c-phase-2b-aspire-study-in-treatment-experienced-genotype-1-patients-122283308.html
